logo

For the Inventor, By the Inventor

Gales Ferry, CT, United States of America

Frank R Busch

USPTO Granted Patents = 16

Average Co-Inventor Count = 2.8

ph-index = 6

Forward Citations = 158(Granted Patents)


Location History:

  • New London, CT (US) (1995)
  • Wauconda, IL (US) (1984 - 2003)
  • Gales Ferry, CT (US) (1991 - 2004)

Company Filing History:

goldMedal14 out of 4,455 
 
Pfizer Corporation
 patents
silverMedal2 out of 832,843 
Other
 patents

Years Active: 1984-2004

Loading Chart...
16 patents (USPTO):Explore Patents
1. 6696574 - Processes and intermediates for preparing glycogen phosphorylase inhibitors (2004-02-24),
2. 6683106 - N-(indole-2-carbonyl)-b-alaninamide crystal forms (2004-01-27),
3. 6673929 - Process for preparing growth hormone secretagogues (2004-01-06),
4. 6627643 - Methods for preparing sodium-hydrogen exchanger type-1 inhibitors (2003-09-30),
5. 6541634 - Process for preparing growth hormone secretagogues (2003-04-01),
6. 6513464 - Two cycle stratified charge gasoline engine (2003-02-04),
7. 6245765 - Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist (2001-06-12),
8. 6150366 - Ziprasidone formulations (2000-11-21),
9. 6110918 - Mesylate trihydrate salt of (2000-08-29),
10. 5606041 - Process for steroidal peracyl glycosides (1997-02-25),
11. 5530107 - Method for making steroidal peracyl glycosides (1996-06-25),
12. 5380860 - Preparation of beta-ketoesters useful in preparing quinolone antibiotics (1995-01-10),
13. 5338846 - Process for preparing aryl piperazinyl-heterocyclic compounds with a (1994-08-16),
14. 5312925 - Monohydrate of (1994-05-17),
15. 5075439 - Processes for (1991-12-24),

Title: Frank R Busch: Innovator in Glycogen Phosphorylase Inhibitors

Introduction

Frank R Busch is a notable inventor based in Gales Ferry, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of glycogen phosphorylase inhibitors. With a total of 16 patents to his name, his work has implications for treating various metabolic diseases.

Latest Patents

Among his latest patents, Busch has developed processes and intermediates for preparing glycogen phosphorylase inhibitors. This invention provides novel processes and intermediates useful in the preparation of certain N-(indole-2-carbonyl)-β-alaninamide compounds. These compounds are glycogen phosphorylase inhibitors that can be beneficial in treating diseases such as hypercholesterolemia, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis, diabetes, diabetic cardiomyopathy, infection, tissue ischemia, myocardial ischemia, and in inhibiting tumor growth. Another significant patent includes the N-(indole-2-carbonyl)-β-alaninamide crystal forms, which further enhance the therapeutic potential of these compounds.

Career Highlights

Throughout his career, Frank R Busch has worked with prominent organizations, including Pfizer Corporation. His innovative approaches and research have positioned him as a key figure in pharmaceutical development.

Collaborations

Busch has collaborated with notable professionals in his field, including Peter Robert Rose and Russell J Shine. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Frank R Busch's contributions to the field of glycogen phosphorylase inhibitors highlight his innovative spirit and dedication to improving health outcomes. His work continues to influence the pharmaceutical industry and offers hope for the treatment of various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…